CAR-T Update: Kite's Filing Coming Soon
Executive Summary
With all eyes on the race to get the autologous cell immunotherapies to market, Kite announces it could soon see late-stage data on its lead candidate.
You may also be interested in...
New Interim CAR-T Data Support Kite’s BLA Submission Plans
Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.
INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve
Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.
Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns
Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.